AngloGold Ashanti Limited (AU) Reaches $11.07 After 3.00% Up Move; COCRYSTAL PHARMA (COCP) Sellers Decreased By 50.08% Their Shorts

January 14, 2018 - By Marie Mckinney

COCRYSTAL PHARMA INCORPORATED (OTCMKTS:COCP) had a decrease of 50.08% in short interest. COCP’s SI was 579,900 shares in January as released by FINRA. Its down 50.08% from 1.16 million shares previously. With 234,800 avg volume, 3 days are for COCRYSTAL PHARMA INCORPORATED (OTCMKTS:COCP)’s short sellers to cover COCP’s short positions. The stock decreased 4.76% or $0.01 during the last trading session, reaching $0.2. About 76,533 shares traded. Cocrystal Pharma, Inc. (OTCMKTS:COCP) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of AngloGold Ashanti Limited (NYSE:AU) is a huge mover today! The stock increased 4.14% or $0.44 during the last trading session, reaching $11.07. About 3.91 million shares traded or 37.49% up from the average. AngloGold Ashanti Limited (NYSE:AU) has declined 18.89% since January 14, 2017 and is downtrending. It has underperformed by 35.59% the S&P500.The move comes after 9 months positive chart setup for the $4.18 billion company. It was reported on Jan, 14 by Barchart.com. We have $11.40 PT which if reached, will make NYSE:AU worth $125.34 million more.

AngloGold Ashanti Limited operates as a gold mining and exploration company. The company has market cap of $4.18 billion. The firm also produces silver, uranium oxide, copper, and sulphuric acid. It currently has negative earnings. The Company’s portfolio includes 17 mines in South Africa, Continental Africa, Australasia, and the Americas.

Among 5 analysts covering Anglogold Ashanti Limited (NYSE:AU), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Anglogold Ashanti Limited had 12 analyst reports since August 18, 2015 according to SRatingsIntel. On Tuesday, March 8 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The firm earned “Buy” rating on Tuesday, November 7 by HSBC. On Monday, January 18 the stock rating was upgraded by Goldman Sachs to “Buy”. RBC Capital Markets downgraded AngloGold Ashanti Limited (NYSE:AU) on Monday, April 24 to “Sector Perform” rating. Citigroup upgraded the shares of AU in report on Tuesday, February 23 to “Neutral” rating. The rating was downgraded by Citigroup to “Sell” on Tuesday, May 10. The stock of AngloGold Ashanti Limited (NYSE:AU) earned “Buy” rating by Goldman Sachs on Friday, January 15. RBC Capital Markets upgraded AngloGold Ashanti Limited (NYSE:AU) on Monday, April 11 to “Outperform” rating. The firm earned “Outperform” rating on Monday, November 13 by RBC Capital Markets.

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company has market cap of $145.65 million. The firm focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It currently has negative earnings. It is developing antiviral therapeutics for human diseases, including hepatitis C virus , influenza virus, and norovirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: